Ptc Therapeutics (PTCT) Non-Current Deferred Tax Liability (2018 - 2024)

Ptc Therapeutics' Non-Current Deferred Tax Liability history runs 7 years deep, the most recent figure standing at $55.9 million for Q3 2024.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 7.67% year-over-year to $55.9 million in Q3 2024; TTM through Sep 2024 was $55.9 million, a 7.67% increase from a year earlier, with the FY2023 full-year figure at $55.9 million, down 45.64% from the prior year.
• Non-Current Deferred Tax Liability held at $55.9 million in Q3 2024 per PTCT's latest filing, from $55.9 million in the prior quarter.
• Across five years, Non-Current Deferred Tax Liability topped out at $137.1 million in Q4 2021 and bottomed at $51.9 million in Q3 2023.
• The 5-year median for Non-Current Deferred Tax Liability is $122.0 million (2021), against an average of $104.0 million.
• Across the five-year window, Non-Current Deferred Tax Liability advanced 12.39% in 2022 and tumbled 62.13% in 2023, its largest moves.
• Year by year, Non-Current Deferred Tax Liability stood at $136.7 million in 2020, then climbed by 0.27% to $137.1 million in 2021, then slipped by 25.0% to $102.8 million in 2022, then slumped by 45.64% to $55.9 million in 2023, then climbed by 0.01% to $55.9 million in 2024.
• Per Business Quant, the three latest PTCT Non-Current Deferred Tax Liability figures stand at $55.9 million (Q3 2024), $55.9 million (Q2 2024), and $55.9 million (Q1 2024).